Cargando…

The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis

PURPOSE: The main purpose of this study was to examine the overall distribution of chronic comorbidities in coronavirus disease-19 (COVID-19) infected populations and the risk of the underlying burden of disease in terms of the case fatality ratio (CFR). METHODS: We carried out a systematic review a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahumud, Rashidul Alam, Kamara, Joseph K., Renzaho, Andre M. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434853/
https://www.ncbi.nlm.nih.gov/pubmed/32813220
http://dx.doi.org/10.1007/s15010-020-01502-8
_version_ 1783572222978293760
author Mahumud, Rashidul Alam
Kamara, Joseph K.
Renzaho, Andre M. N.
author_facet Mahumud, Rashidul Alam
Kamara, Joseph K.
Renzaho, Andre M. N.
author_sort Mahumud, Rashidul Alam
collection PubMed
description PURPOSE: The main purpose of this study was to examine the overall distribution of chronic comorbidities in coronavirus disease-19 (COVID-19) infected populations and the risk of the underlying burden of disease in terms of the case fatality ratio (CFR). METHODS: We carried out a systematic review and meta-analysis of studies on COVID-19 patients published before 10(th) April 2020. Twenty-three studies containing data for 202,005 COVID-19 patients were identified and included in our study. Pooled effects of chronic comorbid conditions and CFR with 95% confidence intervals were calculated using random-effects models. RESULTS: A median age of COVID-19 patients was 56.4 years and 55% of the patients were male. The most prevalent chronic comorbid conditions were: any type of chronic comorbidity (37%; 95% CI 32–41%), hypertension (22%; 95% CI 17–27%), diabetes (14%; 95% CI 12–17%), respiratory diseases (5%; 95% CI 3–6%), cardiovascular diseases (13%; 95% CI 10–16%) and other chronic diseases (e.g., cancer) (8%; 95% CI 6–10%). Furthermore, 37% of COVID-19 patients had at least one chronic comorbid condition, 28% of patients had two conditions, and 19% of patients had three or more chronic conditions. The overall pooled CFR was 7% (95% CI 6–7%). The crude CFRs increased significantly with increasing number of chronic comorbid conditions, ranging from 6% for at least one chronic comorbid condition to 13% for 2 or 3 chronic comorbid conditions, 12% for 4 chronic comorbid conditions, 14% for 5 chronic comorbid conditions, and 21% for 6 or more chronic comorbid conditions. Furthermore, the overall CFRs also significantly increased with higher levels of reported clinical symptoms, ranging from 14% for at least four symptoms, to 15% for 5 or 6 symptoms, and 21% for 7 or more symptoms. CONCLUSIONS: The chronic comorbid conditions were identified as dominating risk factors, which should be considered in an emergency disease management and treatment choices. There is urgent need to further enhance systematic and real-time sharing of epidemiologic data, clinical results, and experience to inform the global response to COVID-19.
format Online
Article
Text
id pubmed-7434853
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-74348532020-08-19 The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis Mahumud, Rashidul Alam Kamara, Joseph K. Renzaho, Andre M. N. Infection Review PURPOSE: The main purpose of this study was to examine the overall distribution of chronic comorbidities in coronavirus disease-19 (COVID-19) infected populations and the risk of the underlying burden of disease in terms of the case fatality ratio (CFR). METHODS: We carried out a systematic review and meta-analysis of studies on COVID-19 patients published before 10(th) April 2020. Twenty-three studies containing data for 202,005 COVID-19 patients were identified and included in our study. Pooled effects of chronic comorbid conditions and CFR with 95% confidence intervals were calculated using random-effects models. RESULTS: A median age of COVID-19 patients was 56.4 years and 55% of the patients were male. The most prevalent chronic comorbid conditions were: any type of chronic comorbidity (37%; 95% CI 32–41%), hypertension (22%; 95% CI 17–27%), diabetes (14%; 95% CI 12–17%), respiratory diseases (5%; 95% CI 3–6%), cardiovascular diseases (13%; 95% CI 10–16%) and other chronic diseases (e.g., cancer) (8%; 95% CI 6–10%). Furthermore, 37% of COVID-19 patients had at least one chronic comorbid condition, 28% of patients had two conditions, and 19% of patients had three or more chronic conditions. The overall pooled CFR was 7% (95% CI 6–7%). The crude CFRs increased significantly with increasing number of chronic comorbid conditions, ranging from 6% for at least one chronic comorbid condition to 13% for 2 or 3 chronic comorbid conditions, 12% for 4 chronic comorbid conditions, 14% for 5 chronic comorbid conditions, and 21% for 6 or more chronic comorbid conditions. Furthermore, the overall CFRs also significantly increased with higher levels of reported clinical symptoms, ranging from 14% for at least four symptoms, to 15% for 5 or 6 symptoms, and 21% for 7 or more symptoms. CONCLUSIONS: The chronic comorbid conditions were identified as dominating risk factors, which should be considered in an emergency disease management and treatment choices. There is urgent need to further enhance systematic and real-time sharing of epidemiologic data, clinical results, and experience to inform the global response to COVID-19. Springer Berlin Heidelberg 2020-08-19 2020 /pmc/articles/PMC7434853/ /pubmed/32813220 http://dx.doi.org/10.1007/s15010-020-01502-8 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Mahumud, Rashidul Alam
Kamara, Joseph K.
Renzaho, Andre M. N.
The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis
title The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis
title_full The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis
title_fullStr The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis
title_full_unstemmed The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis
title_short The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis
title_sort epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434853/
https://www.ncbi.nlm.nih.gov/pubmed/32813220
http://dx.doi.org/10.1007/s15010-020-01502-8
work_keys_str_mv AT mahumudrashidulalam theepidemiologicalburdenandoveralldistributionofchroniccomorbiditiesincoronavirusdisease2019among202005infectedpatientsevidencefromasystematicreviewandmetaanalysis
AT kamarajosephk theepidemiologicalburdenandoveralldistributionofchroniccomorbiditiesincoronavirusdisease2019among202005infectedpatientsevidencefromasystematicreviewandmetaanalysis
AT renzahoandremn theepidemiologicalburdenandoveralldistributionofchroniccomorbiditiesincoronavirusdisease2019among202005infectedpatientsevidencefromasystematicreviewandmetaanalysis
AT mahumudrashidulalam epidemiologicalburdenandoveralldistributionofchroniccomorbiditiesincoronavirusdisease2019among202005infectedpatientsevidencefromasystematicreviewandmetaanalysis
AT kamarajosephk epidemiologicalburdenandoveralldistributionofchroniccomorbiditiesincoronavirusdisease2019among202005infectedpatientsevidencefromasystematicreviewandmetaanalysis
AT renzahoandremn epidemiologicalburdenandoveralldistributionofchroniccomorbiditiesincoronavirusdisease2019among202005infectedpatientsevidencefromasystematicreviewandmetaanalysis